Compare EIC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIC | LUNG |
|---|---|---|
| Founded | N/A | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.8M | 97.1M |
| IPO Year | 2018 | 2020 |
| Metric | EIC | LUNG |
|---|---|---|
| Price | $9.63 | $1.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $12.63 | $5.38 |
| AVG Volume (30 Days) | 81.4K | ★ 330.8K |
| Earning Date | 05-27-2026 | 04-29-2026 |
| Dividend Yield | ★ 13.25% | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | $9.08 | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $9.17 | $1.13 |
| 52 Week High | $13.55 | $2.89 |
| Indicator | EIC | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 39.63 | 46.42 |
| Support Level | $9.33 | $1.20 |
| Resistance Level | $10.14 | $2.16 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 32.08 | 25.12 |
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.